ChAdOx
A chimpanzee adenovirus-based viral-vector vaccine platform developed at the University of Oxford; used in the Oxford-AstraZeneca COVID-19 vaccine and now applied to Bundibugyo ebolavirus vaccine candidates.
Last refreshed: 24 May 2026 · Appears in 1 active topic
How close is the Oxford vaccine platform to having a working Bundibugyo Ebola shot?
Timeline for ChAdOx
Mentioned in: Ebola drug trial awaits DRC, Uganda nod
Pandemics and Biosecurity- What is the ChAdOx vaccine platform and how does it work?
- ChAdOx is a viral-vector platform using a modified chimpanzee adenovirus to deliver antigen instructions into human cells. Developed at Oxford, it was the backbone of the AstraZeneca COVID-19 vaccine and is now being adapted for Ebola and other pathogens.Source: University of Oxford / Jenner Institute
- Is the Oxford Ebola vaccine ready to use in the current outbreak?
- No. As of May 2026 the ChAdOx-based Bundibugyo vaccine candidate is two to three months from being ready for human trials and lacks the safety data required for use in an active outbreak.Source: WHO
- How is the ChAdOx Ebola vaccine different from the COVID-19 vaccine?
- Both use the same viral-vector platform, but the antigen delivered differs: the COVID-19 version (AZD1222) carries the SARS-CoV-2 spike protein, while the Ebola candidate carries Bundibugyo ebolavirus antigens to train the immune system against that species.Source: Jenner Institute, University of Oxford
- Why was the AstraZeneca vaccine used so widely in developing countries?
- The Oxford/AstraZeneca ChAdOx vaccine (AZD1222) was priced for low-income markets, stored at standard refrigerator temperatures rather than ultra-cold, and manufactured at scale in India and elsewhere, making it the most widely distributed COVID-19 vaccine globally.Source: WHO / COVAX
Background
A ChAdOx-platform Bundibugyo ebolavirus vaccine candidate is two to three months from being ready for human trial doses as of May 2026, though it has not yet accumulated the human safety data required for use in an active outbreak. The vaccine lacks regulatory clearance and trial approval; its timeline runs parallel to, but does not affect, the WHO-sponsored therapeutic trial of remdesivir and MBP134.
ChAdOx (chimpanzee adenovirus Oxford) is a viral-vector vaccine platform developed at the Jenner Institute, University of Oxford. It uses a modified, replication-deficient chimpanzee adenovirus to deliver genetic instructions for a target pathogen's antigen into human cells, triggering an immune response. The platform gained global recognition as the basis of the Oxford/AstraZeneca COVID-19 vaccine (AZD1222), which was deployed at enormous scale from late 2020 and was the primary vaccine used across much of the developing world in 2021. The Oxford group subsequently adapted ChAdOx toward vaccine candidates for Ebola, Middle East Respiratory Syndrome (MERS), and other high-priority pathogens.
ChAdOx's key advantage is its established manufacturing infrastructure and its documented safety profile from COVID-19 deployment in hundreds of millions of people, which accelerates regulatory review for new candidates on the same platform. For Bundibugyo specifically, ChAdOx offers a faster route to trial than entirely novel platforms, though it remains further from deployment than the therapeutic options in the current WHO trial. If human safety data for the Bundibugyo ChAdOx candidate accrues during the current outbreak window, it would position the platform as a primary candidate for a future ring-vaccination strategy.